These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

894 related articles for article (PubMed ID: 32832560)

  • 1. The Intricate Relationship between Type 2 Diabetes Mellitus (T2DM), Insulin Resistance (IR), and Nonalcoholic Fatty Liver Disease (NAFLD).
    Tanase DM; Gosav EM; Costea CF; Ciocoiu M; Lacatusu CM; Maranduca MA; Ouatu A; Floria M
    J Diabetes Res; 2020; 2020():3920196. PubMed ID: 32832560
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic fatty liver disease and type 2 diabetes: common pathophysiologic mechanisms.
    Saponaro C; Gaggini M; Gastaldelli A
    Curr Diab Rep; 2015 Jun; 15(6):607. PubMed ID: 25894944
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Concurrent nonalcoholic fatty liver disease and type 2 diabetes: diagnostic and therapeutic considerations.
    Arrese M; Barrera F; Triantafilo N; Arab JP
    Expert Rev Gastroenterol Hepatol; 2019 Sep; 13(9):849-866. PubMed ID: 31353974
    [No Abstract]   [Full Text] [Related]  

  • 4. Non-alcoholic fatty liver disease and type 2 diabetes mellitus: the liver disease of our age?
    Firneisz G
    World J Gastroenterol; 2014 Jul; 20(27):9072-89. PubMed ID: 25083080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is HOMA-IR a potential screening test for non-alcoholic fatty liver disease in adults with type 2 diabetes?
    Gutierrez-Buey G; Núñez-Córdoba JM; Llavero-Valero M; Gargallo J; Salvador J; Escalada J
    Eur J Intern Med; 2017 Jun; 41():74-78. PubMed ID: 28283346
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nonalcoholic Fatty Liver Disease and Diabetes: An Epidemiological Perspective.
    Rhee EJ
    Endocrinol Metab (Seoul); 2019 Sep; 34(3):226-233. PubMed ID: 31565874
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High Prevalence of Nonalcoholic Fatty Liver Disease in Patients With Type 2 Diabetes Mellitus and Normal Plasma Aminotransferase Levels.
    Portillo-Sanchez P; Bril F; Maximos M; Lomonaco R; Biernacki D; Orsak B; Subbarayan S; Webb A; Hecht J; Cusi K
    J Clin Endocrinol Metab; 2015 Jun; 100(6):2231-8. PubMed ID: 25885947
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonalcoholic fatty liver disease: Evolving paradigms.
    Lonardo A; Nascimbeni F; Maurantonio M; Marrazzo A; Rinaldi L; Adinolfi LE
    World J Gastroenterol; 2017 Sep; 23(36):6571-6592. PubMed ID: 29085206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Relationship between Type 2 Diabetes Mellitus and Non-Alcoholic Fatty Liver Disease Measured by Controlled Attenuation Parameter.
    Chon YE; Kim KJ; Jung KS; Kim SU; Park JY; Kim do Y; Ahn SH; Chon CY; Chung JB; Park KH; Bae JC; Han KH
    Yonsei Med J; 2016 Jul; 57(4):885-92. PubMed ID: 27189281
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis.
    Leoni S; Tovoli F; Napoli L; Serio I; Ferri S; Bolondi L
    World J Gastroenterol; 2018 Aug; 24(30):3361-3373. PubMed ID: 30122876
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Type 2 Diabetes Mellitus and Simple Glucose Metabolism Parameters may Reliably Predict Nonalcoholic Fatty Liver Disease Features.
    Cazzo E; Jimenez LS; Gestic MA; Utrini MP; Chaim FHM; Chaim FDM; Pareja JC; Chaim EA
    Obes Surg; 2018 Jan; 28(1):187-194. PubMed ID: 28741239
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Steatosis and NASH in type 2 diabetes.
    Hu M; Phan F; Bourron O; Ferré P; Foufelle F
    Biochimie; 2017 Dec; 143():37-41. PubMed ID: 29097281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-alcoholic fatty liver disease (NAFLD) prevalence and its metabolic associations in patients with type 1 diabetes and type 2 diabetes.
    Cusi K; Sanyal AJ; Zhang S; Hartman ML; Bue-Valleskey JM; Hoogwerf BJ; Haupt A
    Diabetes Obes Metab; 2017 Nov; 19(11):1630-1634. PubMed ID: 28417532
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of aspartate aminotransferase platelet ratio index score and insulin resistance in type 2 diabetes mellitus with non-alcoholic fatty liver disease.
    Gupta N; Ramzaan Dar W; Wani A; Raj Saxena R; Khatri S; Tyagi B; Bansal P; Ahmad Mir I
    Endocr Regul; 2023 Jan; 57(1):106-113. PubMed ID: 37285459
    [No Abstract]   [Full Text] [Related]  

  • 18. Non-Alcoholic Fatty Liver Disease in Patients with Type 2 Diabetes Mellitus: A Position Statement of the Fatty Liver Research Group of the Korean Diabetes Association.
    Lee BW; Lee YH; Park CY; Rhee EJ; Lee WY; Kim NH; Choi KM; Park KG; Choi YK; Cha BS; Lee DH;
    Diabetes Metab J; 2020 Jun; 44(3):382-401. PubMed ID: 32431115
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-alcoholic fatty liver disease, insulin resistance, metabolic syndrome and their association with vascular risk.
    Muzurović E; Mikhailidis DP; Mantzoros C
    Metabolism; 2021 Jun; 119():154770. PubMed ID: 33864798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Non-Alcoholic Fatty Liver Disease and Diabetes: the bad marriage].
    Nascè A; Memaj P; Jornayvaz FR
    Rev Med Suisse; 2023 May; 19(829):1090-1093. PubMed ID: 37260205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 45.